Orbimed Advisors LLC Has $20.43 Million Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Orbimed Advisors LLC increased its position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 91.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,470,086 shares of the company's stock after purchasing an additional 701,448 shares during the quarter. Orbimed Advisors LLC owned 2.91% of Tyra Biosciences worth $20,434,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Alta Partners Management Company L.P. bought a new position in Tyra Biosciences during the 4th quarter valued at $56,716,000. Boxer Capital Management LLC bought a new position in Tyra Biosciences during the 4th quarter valued at $28,185,000. Farallon Capital Management LLC bought a new position in Tyra Biosciences during the 4th quarter valued at $13,914,000. Janus Henderson Group PLC boosted its stake in Tyra Biosciences by 63.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock valued at $24,291,000 after acquiring an additional 679,124 shares during the last quarter. Finally, Pictet Asset Management Holding SA bought a new position in Tyra Biosciences during the 4th quarter valued at $4,921,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock traded up $0.13 during trading hours on Friday, reaching $9.99. The company's stock had a trading volume of 145,379 shares, compared to its average volume of 261,983. The company's 50 day simple moving average is $9.55 and its 200 day simple moving average is $12.83. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $29.60. The stock has a market cap of $530.37 million, a P/E ratio of -6.20 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on TYRA. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.